PURE Bioscience  

(Public, NASDAQ:PURE)   Watch this stock  
Find more results for PURE
0.380
0.000 (-0.08%)
Real-time:   11:00AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.37 - 0.39
52 week 0.22 - 1.05
Open 0.39
Vol / Avg. 27,250.00/138,269.00
Mkt cap 20.77M
P/E     -
Div/yield     -
EPS -0.20
Shares 54.66M
Beta 0.79
Inst. own 3%
Jul 31, 2012
PURE Bioscience Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '12) 2011
Net profit margin -883.57% -1798.68%
Operating margin -882.13% -1802.51%
EBITD margin - -1701.12%
Return on average assets -177.09% -149.87%
Return on average equity -356.38% -173.89%
Employees 25 -
Carbon Disclosure Rating - -

Address

1725 Gillespie Way
EL CAJON, CA 92020
United States - Map
+1-619-5968600 (Phone)
+1-619-5968690 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

PURE Bioscience, Inc., formerly PURE Bioscience, is engaged in the development and commercialization of bioscience technologies. Its flagship bioscience technology is a aqueous antimicrobial called silver dihydrogen citrate (SDC). A molecular entity, SDC is an electrolytically generated source of stabilized ionic silver, which serves as the basis for a range of products in diverse markets. SDC liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. The Company is producing pre-formulated, ready-to-use products for both its own brands and for private label distribution, as well as varying strengths of SDC concentrate as an additive or raw material for inclusion in other companies� products. It is also producing SDC as an active pharmaceutical ingredient, which is in clinical trials for multiple indications. In addition to SDC, it has obtained protection for ionic silver-based molecular entities utilizing 14 organic acids other than citric acid.

Officers and directors

Michael L. Krall Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation - Reuters
Craig A. Johnson Chief Financial Officer
Age: 50
Bio & Compensation - Reuters
Donna M. Singer Executive Vice President, Director
Age: 42
Bio & Compensation - Reuters
Gregory H. Barnhill Independent Director
Age: 59
Bio & Compensation - Reuters
Dennis Brovarone Independent Director
Age: 56
Bio & Compensation - Reuters
John J. Carbone M.D. Independent Director
Age: 50
Bio & Compensation - Reuters
Paul V. Maier Independent Director
Age: 64
Bio & Compensation - Reuters